ADVERTISEMENT
Real-World Data Shows Crizotinib is Effective Treating in ALK+ and ROS1+ NSCLC
According to real-world data, crizotinib is effective in treating French patients with advanced non-small-cell lung cancer (NSCLC) with ALK-positive or ROS1-positive gene rearrangement (Annals of Oncology (2021) 32 (suppl_5): S949-S1039.).
“Crizotinib is the first tyrosine kinase inhibitor authorized for the treatment of aNSCLC ALK+ or ROS1+, regardless of lines. Real-world data is scarce for these populations,” explained Didier Debieuvre, MD, Pneumology, Hopital Emile Muller, Mulhouse, France.
The non-interventional, ambispective, multicentric study included patients with advanced NSCLC that were either ALK+ or ROS1+; and was done in collaboration with CPHG (French College of General Hospital Respiratory Physician).
Of the 73 patients included, 51 were ALK+ and 22 were ROS1+, with the median delay between biopsy and positive result for ALK+ or ROS1+ being 10 and 8 days, respectively. Before crizotinib treatment, 20 patients had chemotherapy, and 9 had radiotherapy. A majority of patients (70; 98.6%) initiated crizotinib at 250mg twice a day, 47 patients started crizotinib before inclusion (≤ 3 months).
The objective response rate (ORR) was 62.7% for ALK+ and 55% for ROS1+ patients. The median progression-free survival (PFS) in the ALK+ and ROS1+ group respectively was 9.4 months (7-16.1) and 6.6 months (4.3-14.2). The median overall survival was not reached in ALK+ patients but was 13.7 months in ROS1+ patients.
Treatment-related adverse events (AEs) occurred in 74% of patients, and serious AEs occurred in 37%. The most common AEs of any cause included diarrhea, nausea, edema, or vision disorders.
“Our results are consistent with other RW in terms of effectiveness and safety. Crizotinib was effective in both ALK+ and ROS1+ aNSCLC in a real-life setting with no new safety concerns,” concluded Dr Debieuvre et al.
